	R 2012 Mar 31	2013 Mar 31	2014 Jun 30	C 2015 Jun 30	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	R 2012 Mar 31	2013 Mar 31	2014 Jun 30	C 2015 Jun 30	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	18M AR	12M AR	15M AR	12M AR	9M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	169.93	127.12	117.52	166.27	130.41	110.08	59.81	70.78	61.49	86.25	194.08	93.07	111.19	138.50	128.44	137.73
Cost of Operating Revenue	113.84	81.02	72.33	101.61	79.75	64.10	40.66	46.56	43.80	46.29	70.32	51.70	62.44	66.66	63.35	62.27
Gross Profit	56.10	46.10	45.19	64.66	50.66	45.98	19.15	24.22	17.69	39.96	123.76	41.38	48.75	71.84	65.09	75.46
Gross Margin	33.0	36.3	38.5	38.9	38.8	41.8	32.0	34.2	28.8	46.3	63.8	44.5	43.8	51.9	50.7	54.8
Total Operating Expenses	163.53	118.92	123.06	149.90	120.47	97.56	74.64	79.99	73.17	74.89	110.28	90.37	108.26	127.31	140.37	148.71
Operating Profit	6.41	8.20	-5.54	16.37	9.94	12.52	-14.83	-9.21	-11.68	11.36	83.80	2.70	2.93	11.19	-11.92	-10.98
Operating Margin	3.8	6.5	-4.7	9.8	7.6	11.4	-24.8	-13.0	-19.0	13.2	43.2	2.9	2.6	8.1	-9.3	-8.0
Financing Income/(Expense) - Net	-27.04	-17.97	-24.93	-24.16	-15.19	-18.74	-9.58	-7.17	-20.07	-25.94	-20.13	-11.87	-3.54	-0.76	-0.34	-3.49
Profit before Taxes	-6.90	-0.71	-5.34	-3.66	3.90	-8.10	-20.04	-15.42	-61.88	-14.14	59.25	-13.17	-0.93	11.12	-11.78	-11.18
Income Taxes	-	-	1.25	1.06	-0.19	-1.51	-1.04	-9.07	0.74	-4.05	20.80	-0.02	1.69	3.19	-1.34	-1.80
Profit after Tax	-6.90	-0.71	-6.59	-4.95	3.69	-5.54	-17.27	-5.55	-60.54	-11.55	39.00	-13.21	-2.49	8.01	-10.03	-8.90
PAT Margin	-4.1	-0.6	-5.6	-3.0	2.8	-5.0	-28.9	-7.8	-98.5	-13.4	20.1	-14.2	-2.2	5.8	-7.8	-6.5
EPS - Basic - ex Extraordinary Items	-2.72	-0.67	-3.12	-2.34	1.65	-2.51	-6.69	-1.97	-21.25	-4.03	13.59	-4.59	-0.75	2.25	-2.81	-2.50
EPS - Diluted - ex Extraordinary Items	-2.72	-0.67	-3.12	-2.34	1.65	-2.51	-6.69	-1.97	-21.25	-4.03	13.59	-4.59	-0.75	2.25	-2.81	-2.50
EBIT	6.41	8.20	-5.54	16.37	9.94	12.52	-14.83	-9.21	-11.68	11.36	83.80	2.70	2.93	11.19	-11.92	-10.98
EBITDA	15.05	19.90	3.26	27.24	19.26	24.13	-2.19	-1.90	-3.67	19.68	101.15	16.84	15.74	17.94	-3.49	-2.65
EBITDA Margin	8.9	15.7	2.8	16.4	14.8	21.9	-3.7	-2.7	-6.0	22.8	52.1	18.1	14.2	12.9	-2.7	-1.9

Balance Sheet

Abridged

Understanding Balance Sheet

Lyka Labs Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	R 2014 Jun 30	2015 Jun 30	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Mar 31	R 2014 Jun 30	2015 Jun 30	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	115.01	127.24	118.09	101.69	59.78	62.79	49.07	35.11	35.88	29.12	52.20	44.20	50.65	67.43	63.28
Long-Term Investments	5.52	5.53	0.30	0.32	14.33	14.66	15.46	15.82	13.19	13.77	14.37	16.34	0.07	0.02	-
Property Plant & Equipment - Net	84.34	99.98	103.57	74.38	101.42	99.08	94.01	91.37	89.12	83.66	85.60	63.67	68.84	77.10	82.26
Total Non-Current Assets	167.51	161.66	211.17	177.08	185.82	188.98	180.11	180.77	164.29	160.89	133.42	107.32	106.20	108.77	111.26
Total Assets	282.53	288.90	329.27	278.76	245.60	251.76	229.18	215.88	200.17	190.01	185.61	151.52	156.86	176.21	174.54
Total Current Liabilities	132.46	147.21	208.09	194.59	162.76	165.45	167.12	84.81	66.32	49.24	99.35	32.60	37.77	46.63	53.90
Long Term Debt	70.59	67.22	58.00	28.92	25.86	35.77	4.93	79.28	126.10	151.36	62.49	65.87	44.17	19.90	22.99
Total Non-Current Liabilities	74.49	71.93	65.16	37.60	30.04	41.58	9.23	85.31	148.96	165.87	72.77	73.25	50.82	25.99	29.81
Total Liabilities	206.95	219.14	273.25	232.19	192.79	207.03	176.35	170.12	215.28	215.10	172.12	105.85	88.59	72.62	83.70
Total Shareholders' Equity	73.88	66.95	52.71	43.06	44.69	37.71	49.47	43.02	-14.34	-25.80	13.34	45.44	68.15	103.55	92.39
Minority Interest	1.70	2.81	3.30	3.51	8.12	7.03	3.36	2.74	-0.77	0.70	0.15	0.23	0.11	0.03	-1.56
Total Equity	75.57	69.76	56.02	46.57	52.81	44.74	52.82	45.76	-15.11	-25.09	13.49	45.67	68.27	103.58	90.83
Total Liabilities & Equity	282.53	288.90	329.27	278.76	245.60	251.76	229.18	215.88	200.17	190.01	185.61	151.52	156.86	176.21	174.54

Cash Flow

Abridged

Understanding Cash Flow Statement

Lyka Labs Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Jun 30	2015 Jun 30	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Mar 31	2014 Jun 30	2015 Jun 30	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	18M AR	12M AR	15M AR	12M AR	9M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	-8.30	-3.19	7.66	-3.16	5.58	3.26	-8.61	-8.03	-24.13	14.67	78.61	9.65	8.14	14.57	6.11
Working Capital - Increase/(Decrease)	-16.37	-2.73	58.51	5.93	-7.57	10.10	10.36	27.65	10.94	-11.64	-21.01	-9.86	-13.80	-14.65	-2.50
Net CF from Operating Activities	-24.67	-5.93	66.17	2.77	-1.99	13.36	1.75	19.62	-13.19	3.03	57.60	-0.21	-5.66	-0.08	3.61
Capital Expenditures - Net	-9.18	-2.27	63.71	-28.14	-16.42	12.89	3.50	4.09	1.10	1.27	7.51	-6.31	9.23	12.34	11.13
Net CF from Investing Activities	9.18	2.28	-58.47	28.14	16.42	-12.81	-3.50	-4.09	-1.10	-1.27	-7.51	6.31	-9.23	-12.26	-11.10
Stock - Issuance/(Retirement) - Net	-	-	-	0.32	0.97	-	6.86	-	2.27	-	-	45.34	25.11	27.20	-3.26
Debt - LT & ST - Issuance/(Retirement) - Total	12.19	6.61	-1.80	-35.43	-16.36	-0.98	-35.25	-16.25	20.24	-4.91	-40.19	-56.78	-15.98	-19.47	10.77
Net Cash Flow from Financing Activities	12.19	6.61	-1.80	-35.11	-15.39	-0.98	-0.94	-16.25	22.51	-4.91	-40.19	-11.44	9.13	7.73	7.51
Free Cash Flow to Equity	-3.31	2.96	0.67	-4.51	-1.92	-0.51	-37.00	-0.72	5.95	-3.15	9.90	-50.68	-30.87	-31.89	3.24
Free Operating CF net dividend	-37.34	-18.50	1.87	-4.04	-7.00	-0.02	-1.86	14.80	-14.29	1.76	50.09	-8.40	-14.89	-15.73	-7.52
Free Operating CF	-37.34	-18.50	1.87	-4.04	-7.00	-0.02	-1.86	14.80	-14.29	1.76	50.09	-8.40	-14.89	-15.73	-7.52

Business Segment Analysis

FY End:

Mar 26

Lyka Labs Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 11.13 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 128.44 Cr

Assets

Pharmaceuticals (100.0%)₹ 174.54 Cr

Operating Income

Pharmaceuticals (100.0%)₹ -11.92 Cr

Regional Segment Analysis

FY End:

Mar 26

Lyka Labs Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Domestic (68.8%)₹ 85.61 CrROW (31.2%)₹ 38.74 Cr

Historical Segment Analysis

Track how Lyka Labs Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceuticals	9	16	11

Frequently Asked Questions

What is the revenue of Lyka Labs Ltd.?

The latest trailing twelve month revenue of Lyka Labs Ltd. is ₹ 137.73 Cr, reflecting a 1-year growth of -2.60% and a 3-year CAGR of 15.90%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Lyka Labs Ltd.?

The latest trailing twelve month net profit (PAT) of Lyka Labs Ltd. is ₹ -8.92 Cr, with a 3-year earnings CAGR of 22.48%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Lyka Labs Ltd.?

The trailing twelve month EBITDA of Lyka Labs Ltd. is approximately ₹ -10.98 Cr (based on an operating margin of -7.97%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Lyka Labs Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Lyka Labs Ltd. is -2.50. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Lyka Labs Ltd.?

The debt-to-equity ratio of Lyka Labs Ltd. stands at 0.53. The interest coverage ratio is -3.15x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Lyka Labs Ltd.?

The estimated book value per share of Lyka Labs Ltd. is 25.05 (derived from a P/B ratio of 2.94 and market price of ₹ 73.59), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Lyka Labs Ltd.?

The trailing twelve month operating cash flow of Lyka Labs Ltd. is ₹ 3.61 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Lyka Labs Ltd. report consolidated or standalone financials?

Lyka Labs Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.